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Abstract 1 
Case: A 64-year-old male suffered a pathologic left femoral neck fracture. Biopsy demonstrated 2 
metastatic urothelial cancer with a non-muscle invasive bladder cancer primary confirmed by 3 
cystoscopy. Patient underwent hemiarthroplasty, chemotherapy, radiation, and eventually, a 4 
conversion to total hip arthroplasty. Today, over a decade from initial surgery, the patient 5 
remains alive and highly functional. To our knowledge, this is the only report of bone metastatic 6 
bladder cancer with over 10-year survival. 7 
Conclusion: Bladder cancer metastatic to bone has a 5-year survival rate of 3%. Surgical 8 
resection of metastasis with reconstruction may confer a survival benefit in bony 9 
oligometastatic bladder cancer.  10 
Introduction 11 
Bladder cancer represents a spectrum of disease from less aggressive, non-muscle 12 
invasive to highly aggressive forms, of which all maintain the ability to metastasize. 13 
Metastasis to bone is somewhat common when the carcinoma is muscle invasive, ranging from 14 
approximately 14% – 32% of all metastatic bladder carcinoma cases.1 2 Non-muscle invasive 15 
bladder cancer (NMIBC) metastasizes in less than 10% of cases, typically to lymph nodes.3 16 
Depending on the type, bladder cancer is treated with either radical cystectomy or transurethral 17 
resection, combined with radiation and chemotherapy. 18 
2 
 
Overall, once bladder cancer has metastasized to bone there is a very poor prognosis.4 19 
Studies have reported a 5-year survival rate of 3% and a median overall survival period of 6.2 20 
months.5 6 There currently remains no consensus on surgical treatment of bony metastasis, 21 
with the strongest treatment recommendation being initiation of bisphosphonates or 22 
zoledronic acid to decrease skeletal related events.7 8 9 Management of pathologic or 23 
impending fractures is similar to that of other cancers including lung, breast, and prostate 24 
where intralesional stabilization is typical. We report an extremely rare case of a gentleman 25 
who is cancer free and highly mobile over a decade following a diagnosis and surgical 26 
management of NMIBC metastatic to the left hip. Our patient was informed that information 27 
concerning his case would be described in this report and submitted for publication, to which he 28 
agreed. 29 
Case Description 30 
A 64-year-old gentleman presented to our orthopedic clinic with a one-month history of 31 
left hip pain. Plain radiographs revealed a lytic lesion of the left femoral neck (Fig. 1). A CT 32 
guided biopsy was scheduled to evaluate the etiology of the lesion, with plans for prophylactic 33 
stabilization if metastatic versus wide resection if primary.  34 
Before scheduled biopsy, on September 17th, 2008, the patient had a near fall when his 35 
hip suddenly “buckled”. Radiographs demonstrated a new pathologic, displaced femoral neck 36 
fracture (Fig. 2). Patient was admitted and underwent CT guided biopsy. Following the return of 37 
pathology consistent with metastatic disease, patient underwent left hip cemented bipolar 38 
hemiarthroplasty (Fig. 3). As standard procedure, the femoral head and neck were resected, 39 
essentially performing a surgical metastasectomy of the lesion.   40 
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Final pathology demonstrated transitional cell type morphology and was positive for 41 
cytokeratin (CK) 7 and CK20 confirming urothelial malignancy. Biopsy stained negative for 42 
thyroid transcription factor (TTF), CD45, chromogranin, prostate specific antigen (PSA), and 43 
S100 protein, helping to rule-out other primaries, including lung cancer, lymphoma, 44 
neuroendocrine, prostate, and melanoma (Fig. 4).  45 
A CT thorax/abdomen/pelvis did not reveal other metastases or sites concerning for 46 
primary tumor. PET scan demonstrated increased uptake in the left proximal femur and right 47 
pubic bone with physiologic uptake in the bladder. The patient began palliative radiation 48 
therapy of bony metastasis, which consisted of 3000 centigrays (cGy) in ten fractions to left 49 
hip and 2000 cGy in five fractions to the right pubic bone. During work-up to identify the 50 
primary tumor, cystoscopy was performed where an exophytic bladder lesion was identified, 51 
underwent transurethral resection, and sent for pathology. Biopsy was consistent with 52 
transitional carcinoma, papillary, non-invasive, and low grade with muscularis propria present. 53 
During cystoscopy prostate core needle biopsy was also performed and was positive for 54 
adenocarcinoma in 3 out of 6 cores. Concurrent prostate adenocarcinoma is found in 25-46% 55 
of patients undergoing cystoscopy for bladder cancer.7 Hematology/oncology began 56 
simultaneous treatment for both bladder and prostate primaries with combination 57 
chemotherapy and radiation. Gemcitabine 1000 mg/m2 and cisplatin 70mg/m2 cycles were 58 
completed followed by 4600 cGy of radiation to the bladder and prostate in 23 fractions. At 59 
a little over 2 years from initial fracture patient remained alive and asymptomatic. Patient was 60 
given a 4-week course of zoledronic acid by Hematology/Oncology, and considered cancer free 61 
with no plans for future imaging or studies without new symptoms.  62 
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Upon orthopedic follow-up 21/2 years out from initial hemiarthroplasty, there was 63 
evidence of hemiarthroplasty hardware migrating proximally into the acetabular dome (Fig. 5). 64 
As patient was now cancer free per hematology/oncology patient underwent conversion to a total 65 
hip arthroplasty (THA) (Fig. 6). Over the next 24 months, the patient continued to do well 66 
despite the development of a chronic draining sinus. 2-stage revision was discussed, however 67 
patient declined and instead was placed on Bactrim DS for chronic suppression. 68 
2 years following THA conversion, our patient presented with a significant increase in 69 
hip pain, which was determined to be loosening of the femoral components (Fig. 7). At this time 70 
the patient was agreeable to a 2-stage revision and subsequently underwent explant and antibiotic 71 
spacer placement. 3 months later, patient underwent the second stage with revision to a long 72 
stem, uncemented femoral component (Fig 8). Unfortunately, the patient developed an acute 73 
infection and was taken back for irrigation and debridement (I&D) with polyethylene exchange. 74 
The patient was initiated on ceftaroline acutely followed by chronic suppressive Bactrim DS 75 
and Rifampin, for which he has taken since 2013.  76 
For the past 6 years this patient has had good functional use of the hip, without major 77 
complication besides intermittent development of a draining sinus. Suppressive therapy has 78 
allowed hardware to be retained and functional without any episodes of systemic infection. 79 
He was cleared to return to work as a painter in 2014. As of this publishing, the patient remains 80 
alive and highly mobile with minimal hip pain eleven years following metastatic transitional cell 81 
carcinoma diagnosis. 82 
Discussion  83 
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Bladder cancer is a relatively common malignancy that, when metastasizes, 84 
portends a poor prognosis. Bladder cancer is generally categorized as muscle invasive or 85 
non-muscle invasive. The literature has limited descriptions of NMIBC metastatic to bone. In 86 
one study only 5 patients developed bone metastases without evidence of primary site invasion, 87 
among 1,000 total patients with bladder cancer.10 Case reports have described bony metastatic 88 
NMIBC which include metastases to the hand, foot, and knee.11 12 13 When any form of bladder 89 
cancer metastasizes to bone, the outcome is poor. 5-year survival rate is about 3% with mean 90 
survival time from 6 to 26 months.5 6 14 As of the writing of this manuscript we are aware of no 91 
metastatic bladder cancer patients with over 10-year survival. 92 
There are several reasons that may have contributed to our patient’s remarkable 93 
course. Although, the initial hemiarthroplasty surgery was not intended to be curative, by 94 
removing the femoral head and neck a metastasectomy of the lesion was performed. There 95 
are no studies that have evaluated wide versus marginal resection in metastatic bladder 96 
cancer, however there is evidence that wide resection improves survival in single and 97 
oligometastatic renal cell carcinoma (RCC).1516 Some controversy does remain with data 98 
suggesting any debulking of metastatic RCC, including intralesional resection, improves 99 
survival.17 Our patient appears to have been oligometastatic with lesions of the femoral 100 
neck and pubic bone, however only the primary tumor and femoral neck lesion were 101 
biopsy confirmed. While initial plans were for intralesional stabilization, following 102 
fracture, hemiarthroplasty was pursued given the displaced nature of the femoral neck 103 
fracture. By subsequently removing the entire femoral head and neck, the patient may 104 
have benefited from surgical metastasectomy. The survival of this patient raises the 105 
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question of whether oligometastatic NMIBC patients, similar to RCC patients, may benefit 106 
from undergoing surgical tumor debulking. 107 
Of note, our patient did suffer from a long-standing infection of the THA prompting 108 
suppression chronically with Bactrim DS and Rifampin. Traditionally chronic infection 109 
and/or inflammation has been associated with immunosuppression and a tumor-friendly 110 
microenvironment.18 There are well-established relationships between infectious agents, 111 
including viruses and bacteria, and certain cancer types.19 Some viruses appear to exhibit 112 
oncolytic properties, thought to be a result of preferential infection of tumor cells and/or 113 
priming of the immune response.20 Currently we are aware of no evidence that suggests 114 
bacterial infection may impede tumor growth, however it is possible this had some effect on 115 
our patient’s local tumor environment. Interestingly there is some preliminary research 116 
demonstrating tumor suppressive effects of Rifampin primarily via anti-angiogenic 117 
properties.21 Importantly, in the case presented, chronic antibiotic intervention was begun 118 
over 2 years after diagnosis and Rifampin was not initiated until over 4 years after 119 
diagnosis.  120 
Given the rarity of oligometastatic bladder cancer to bone, there is very little 121 
literature to guide surgical management. When curative radical cystectomy is not possible, 122 
combined chemotherapy and radiation are the recommended treatments. Surgical 123 
metastasectomy may increase survival rates in bony oligometastatic bladder cancer, similar 124 
to single and oligometastatic renal cell carcinoma. Due to persistently low survival rates in 125 
metastatic bladder cancer, future research should investigate this possibly life-prolonging 126 
measure in a larger cohort. 127 
Conclusion  128 
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NMIBC metastasis to bone is a rare event, with a poor prognosis. We present the 129 
exceptional case of a patient who remains alive and highly functional over 10 years following 130 
NMIBC pathologic femoral neck fracture. Combined chemotherapy, radiation, and surgical 131 
metastasectomy with reconstruction may confer a survival benefit in metastatic bladder 132 
cancer.  133 
Figure Legend 134 
 135 




Figure 2. Pathologic femoral neck fracture 138 
  139 
  140 
Figure 3. H&E stain, CK7 stain, CK20 stain, TFF, and Chromogranin stains consistent with 141 
urothelial (transitional) cell carcinoma 142 





Figure 4. Evidence of proximal migration of hemiarthroplasty into the acetabular dome 144 
 145 




Figure 6. Loosening of the femoral components of the THA with lucency around the femoral 148 
stem 149 
 150 
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